The hit to lead phase is a critical phase of drug discovery programs. The main aim of H2L is to find the appropriate leads to move along the pathway to a final clinically active drug. Hit discovery technologies range from traditional high-throughput screening to affinity selection of large libraries, fragment-based techniques, and computer-aided de novo design. Creative Biolabs provides hit-to-lead services to help you determine various physical, biological, and chemical characteristics of the hits. Our H2L process is initiated from the identification of a true structure-activity relationship (SAR) in a series of hits for biological targets.

This brochure details our comprehensive services. Parts of the content are as follows:

1. Hit Discovery & Generation
2. Lead Identification and Early Optimization
3. Hit Characterization
4. Molecular Engineering
5. Chemical Synthesis
6. Structure-Based Drug Design
7. In Vitro Functional Assays & Anti-Tumor Efficacy
8. In Vitro ADME